{
    "title": "111_s422",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Heart Disease Education, Analysis \nResearch, and Treatment for Women Act'' or the ``HEART for Women Act''.\n\nSEC. 2. REPORTING OF DATA IN APPLICATIONS FOR DRUGS, BIOLOGICS, AND \n              DEVICES.\n\n    (a) Drugs.--\n            (1) New drug applications.--Section 505(b) of the Federal \n        Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) is amended--\n                    (A) in paragraph (1), in the second sentence--\n                            (i) by striking ``drug, and (G)'' and \n                        inserting ``drug; (G)''; and\n                            (ii) by inserting before the period the \n                        following: ``; and (H) the information required \n                        under paragraph (7)''; and\n                    (B) by adding at the end the following:\n    ``(7)(A) With respect to clinical data in an application under this \nsubsection, the Secretary may deny such an application if the \napplication fails to meet the requirements of sections 314.50(d)(5)(v) \nand 314.50(d)(5)(vi)(a) of title 21, Code of Federal Regulations.\n    ``(B) The Secretary shall modify the sections referred to in \nsubparagraph (A) to require that an application under this subsection \ninclude any clinical data possessed by the applicant that relates to \nthe safety or effectiveness of the drug involved by gender, age, and \nracial subgroup.\n    ``(C) Promptly after approving an application under this \nsubsection, the Secretary shall, through an Internet site of the \nDepartment of Health and Human Services, make available to the public \nthe information submitted to the Secretary pursuant to subparagraphs \n(A) and (B), subject to sections 301(j) and 520(h)(4) of this Act, \nsubsection (b)(4) of section 552 of title 5, United States Code \n(commonly referred to as the `Freedom of Information Act'), and other \nprovisions of law that relate to trade secrets or confidential \ncommercial information.\n    ``(D) The Secretary shall develop guidance for staff of the Food \nand Drug Administration to ensure that applications under this \nsubsection are adequately reviewed to determine whether the \napplications include the information required pursuant to subparagraphs \n(A) and (B).''.\n            (2) Investigational new drug applications.--Section 505(i) \n        of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) \n        is amended--\n                    (A) in paragraph (2), by striking ``Subject to \n                paragraph (3),'' and inserting ``Subject to paragraphs \n                (3) and (5),'' ; and\n                    (B) by adding at the end the following:\n    ``(5)(A) The Secretary may place a clinical hold (as described in \nparagraph (3)) on an investigation if the sponsor of the investigation \nfails to meet the requirements of section 312.33(a) of title 21, Code \nof Federal Regulations.\n    ``(B) The Secretary shall modify the section referred to in \nsubparagraph (A) to require that reports under such section include any \nclinical data possessed by the sponsor of the investigation that \nrelates to the safety or effectiveness of the drug involved by gender, \nage, and racial subgroup.''.\n    (b) Biologics License Applications.--Section 351 of the Public \nHealth Service Act (42 U.S.C. 262) is amended by adding at the end the \nfollowing:\n    ``(k) The provisions of section 505(b)(7) of the Federal Food, \nDrug, and Cosmetic Act (relating to clinical data submission) apply \nwith respect to an application under subsection (a) of this section to \nthe same extent and in the same manner as such provisions apply with \nrespect to an application under section 505(b) of such Act.''.\n    (c) Devices.--\n            (1) Premarket approval.--Section 515 of the Federal Food, \n        Drug, and Cosmetic Act (21 U.S.C. 360e) is amended--\n                    (A) in subsection (c)(1)--\n                            (i) in subparagraph (G)--\n                                    (I) by moving the margin 2 ems to \n                                the left; and\n                                    (II) by striking ``and'' after the \n                                semicolon at the end;\n                            (ii) by redesignating subparagraph (H) as \n                        subparagraph (I); and\n                            (iii) by inserting after subparagraph (G) \n                        the following subparagraph:\n            ``(H) the information required under subsection (d)(7); \n        and''; and\n                    (B) in subsection (d), by adding at the end the \n                following paragraph:\n    ``(7) To the extent consistent with the regulation of devices, the \nprovisions of section 505(b)(7) (relating to clinical data submission) \napply with respect to an application for premarket approval of a device \nunder subsection (c) of this section to the same extent and in the same \nmanner as such provisions apply with respect to an application for \npremarket approval of a drug under section 505(b).''.\n            (2) Investigational devices.--Section 520(g)(2) of the \n        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360j(g)(2)) is \n        amended by adding at the end the following subparagraph:\n    ``(D) To the extent consistent with the regulation of devices, the \nprovisions of section 505(i)(5) (relating to individual study \ninformation) apply with respect to an application for an exemption \npursuant to subparagraph (A) of this paragraph to the same extent and \nin the same manner as such provisions apply with respect to an \napplication for an exemption under section 505(i).''.\n    (d) Rules of Construction.--This Act and the amendments made by \nthis Act may not be construed--\n            (1) as establishing new requirements under the Federal \n        Food, Drug, and Cosmetic Act relating to the design of clinical \n        investigations  that were not otherwise in effect on the day \n        before the date of the enactment of this Act; or\n            (2) as having any effect on the authority of the Secretary \n        of Health and Human Services to enforce regulations under the \n        Federal Food, Drug, and Cosmetic Act that are not expressly \n        referenced in this Act or the amendments made by this Act.\n    (e) Application.--This section and the amendments made by this \nsection apply only with respect to applications received under section \n505 or 515 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355, \n360e) or section 351 of the Public Health Service Act (42 U.S.C. 262) \non or after the date of the enactment of this Act.\n\nSEC. 3. REPORTING AND ANALYSIS OF PATIENT SAFETY DATA.\n\n    (a) Data Standards.--Section 923(b) of the Public Health Service \nAct (42 U.S.C. 299b-23(b)) is amended by adding at the end the \nfollowing: ``The Secretary shall provide that all nonidentifiable \npatient safety work product reported to and among the network of \npatient safety databases be stratified by sex.''.\n    (b) Use of Information.--Section 923(c) of the Public Health \nService Act (42 U.S.C. 299b-23(c)) is amended by adding at the end the \nfollowing: ``Such analyses take into account data that specifically \nrelates to women and any disparities between treatment and the quality \nof care between males and females.''.\n\nSEC. 4. QUALITY OF CARE REPORTS BY THE AGENCY FOR HEALTHCARE RESEARCH \n              AND QUALITY.\n\n    Section 903 of the Public Health Service Act (42 U.S.C. 299a-1) is \namended--\n            (1) in subsection (b)(1)(B), by inserting before the \n        semicolon the following: ``, and including quality of and \n        access to care for women with heart disease, stroke, and other \n        cardiovascular diseases''; and\n            (2) in subsection (c), by adding at the end the following:\n            ``(4) Annual report on women and heart disease.--Not later \n        than September 30, 2011, and annually thereafter, the \n        Secretary, acting through the Director, shall prepare and \n        submit to Congress a report concerning the findings related to \n        the quality of and access to care for women with heart disease, \n        stroke, and other cardiovascular diseases. The report shall \n        contain recommendations for eliminating disparities in, and \n        improving the treatment of, heart disease, stroke, and other \n        cardiovascular diseases in women.''.\n\nSEC. 5. EDUCATIONAL CAMPAIGNS.\n\n    (a) Distribution of Educational Material.--The Secretary of Health \nand Human Services (referred to in this section as the ``Secretary'') \nshall develop and distribute to females who are age 65 or older, \nphysicians, and other appropriate healthcare professionals, educational \nmaterials relating to the prevention, diagnosis, and treatment of heart \ndisease, stroke, and cardiovascular diseases in women. The Secretary \nmay carry out this subsection through contracts with public and private \nnonprofit entities.\n    (b) Healthcare Professional Educational Campaign.--The Secretary, \nacting through the Bureau of Health Professions of the Health Resources \nand Services Administration, shall conduct an education and awareness \ncampaign for physicians and other healthcare professionals relating to \nthe prevention, diagnosis, and treatment of heart disease, stroke, and \nother cardiovascular diseases in women. The Bureau of Health \nProfessions may carry out this subsection through contracts with public \nand private nonprofit entities.\n\nSEC. 6. EXTENSION OF WISEWOMAN PROGRAM.\n\n    Section 1509 of the Public Health Service Act (42 U.S.C. 300n-4a) \nis amended--\n            (1) in subsection (a)--\n                    (A) by striking the heading and inserting ``In \n                General.--''; and\n                    (B) in the matter preceding paragraph (1), by \n                striking ``may make grants'' and all that follows \n                through ``purpose'' and inserting the following: ``may \n                make grants to such States for the purpose''; and\n            (2) in subsection (d)(1), by striking ``there are \n        authorized'' and all that follows through the period and \n        inserting ``there are authorized to be appropriated $70,000,000 \n        for fiscal year 2010, $73,500,000 for fiscal year 2011, \n        $77,000,000 for fiscal year 2012, $81,000,000 for fiscal year \n        2013, and $85,000,000 for fiscal year 2014.''."
}